EGFR-directed radioimmunotherapy combined with chemotherapy and DNA repair inhibition: development towards clinical application for aggressive cancers

胰腺导管腺癌(PDAC)和三阴性乳腺癌(TNBC)是临床上缺乏有效治疗方法的侵袭性疾病。针对PDAC和TNBC，开发了一种新的治疗方法，包括靶向放疗联合化疗和抑制DNA损伤反应。该项目将开发一个“临床前数据包”，包括生物学原理以及安全性和有效性的临床前证据，这些都将证明早期临床试验是合理的。这套方案包括配方的选择、作用机制和安全性研究。这一进展将对PDAC和TNBC患者产生直接影响，并对其他EGFR阳性癌症产生未来影响。

Pancreatic ductal adenocarcinoma (PDAC) and triple negative breast cancer (TNBC) are aggressive diseases which lack effective therapies in clinical use. A novel and curative therapy was developed against PDAC and TNBC which involves targeted radiotherapy combined with chemotherapy and DNA damage response inhibition. This project will develop a “preclinical data package” comprising a biological rationale and preclinical evidence of safety and efficacy that together would justify an early phase clinical trial. This package includes the choice of formulations, mechanism of action and safety studies. This development will have an immediate impact for PDAC and TNBC patients and a future impact on other EGFR-positive cancers.